Journal Article

Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy

Bartlett, David L, Feist, Mathilde, Lotze, Michael T, Guo, Zong Sheng, Ravindranathan, Roshni, Giehl, Esther, Obermajer, Natasa, Zhu, Zhi, Kammula, Udai S, Kowalsky, Stacy J, Lee, Andrew J. H, Dai, Enyong, Liu, Zuqiang, Ma, Congrong

2021

Overview

Adoptive cell therapy (ACT) using tumor-specific tumor-infiltrating lymphocytes (TILs) has demonstrated success in patients where tumor-antigen specific TILs can be harvested from the tumor, expanded, and re-infused in combination with a preparatory regimen and IL2. One major issue for non-immunogenic tumors has been that the isolated TILs lack tumor specificity and thus possess limited in vivo therapeutic function. An oncolytic virus (OV) mediates an immunogenic cell death for cancer cells, leading to elicitation and dramatic enhancement of tumor-specific TILs. We hypothesized that the tumor-specific TILs elicited and promoted by an OV would be a great source for ACT for solid cancer. In this study, we show that a local injection of oncolytic poxvirus in MC38 tumor with low immunogenicity in C57BL/6 mice, led to elicitation and accumulation of tumor-specific TILs in the tumor tissue. Our analyses indicated that IL2-armed OV-elicited TILs contain lower quantities of exhausted PD-1hiTim-3+ CD8+ T cells and regulatory T cells. The isolated TILs from IL2-expressing OV-treated tumor tissue retained high tumor specificity after expansion ex vivo. These TILs resulted in significant tumor regression and improved survival after adoptive transfer in mice with established MC38 tumor. Our study showcases the feasibility of using an OV to induce tumor-reactive TILs that can be expanded for ACT.

• Publisher: Nature Publishing Group
• Subject: Adoptive transfer / CD8 antigen / Cell death / Cell therapy / Feasibility studies / Immune response / Immunogenicity / Immunoregulation / Interleukin 2 / Lymphocytes T / Oncolysis / Tumor-infiltrating lymphocytes